Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  New England Journal of Medicine

• Publication date

  2009-05-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa0806285PMID 19213681
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

  2010cited by this paper
• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

  2010cited by this paper
• Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity

  2008cited by this paper
• Exploring the anti-tumour activity of bisphosphonates in early breast cancer.

  2008cited by this paper
• Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

  2008cited by this paper
• Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

  2008cited by this paper
• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

  2008cited by this paper
• Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.

  2008cited by this paper
• Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

  2008cited by this paper
• Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow

  2008cited by this paper
• Effect of zoledronic acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer

  2008cited by this paper
• A controlled prospective randomized placebo-controlled trial of Zoledronic acid in bony metastatic bladder cancer patients

  2008cited by this paper
• Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

  2007cited by this paper
• Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

  2007cited by this paper
• Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006.

  2007cited by this paper
• Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

  2007cited by this paper
• Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.

  2007cited by this paper
• Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients

  2007cited by this paper
• Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?

  2007cited by this paper
• Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.

  2007cited by this paper
• Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

  2007cited by this paper
• Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

  2007cited by this paper
• Meta-analysis of clodronate and breast cancer survival

  2007cited by this paper
• Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

  2007cited by this paper
• Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma

  2007cited by this paper
• Benefit of taxanes as adjuvant chemotherapy for early breast cancer

  2006cited by this paper
• Basic principles in the planning of clinical trials in surgical oncology

  2006cited by this paper
• Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer.

  2006cited by this paper
• Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.

  2006cited by this paper
• A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

  2005cited by this paper
• Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

  2005cited by this paper
• Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

  2005cited by this paper
• Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline

  2005cited by this paper
• Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

  2005cited by this paper
• Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer Model

  2004cited by this paper
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

  2004cited by this paper
• Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer

  2004cited by this paper
• A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

  2003cited by this paper
• Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998.

  2003cited by this paper
• Zoledronic Acid Treatment of 5T2MM‐Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival

  2003cited by this paper
• Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.

  2002cited by this paper
• American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

  2002cited by this paper
• The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

  2001cited by this paper
• Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

  2001cited by this paper
• Bisphosphonates induce apoptosis in human breast cancer cell lines

  2000cited by this paper
• Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma

  2000cited by this paper
• Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.

  2000cited by this paper
• Reduction in new metastases in breast cancer with adjuvant clodronate treatment.

  1998cited by this paper
• Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1996cited by this paper
• Ovarian ablation in early breast cancer: Overview of the randomised trials

  1996cited by this paper
• Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer.

  1990cited by this paper
• A new look at the statistical model identification

  1974cited by this paper

• Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer.

  2026cites this paper
• Bone Health Assessment and Management among Survivors of Non-metastatic Breast Cancer: A Narrative Review

  2025cites this paper
• The impact of analysis methodology details on invasive breast cancer-free survival in randomized clinical trials

  2025cites this paper
• Navigating skeletal wellness after breast cancer.

  2025cites this paper
• Research Trends in Immunomodulatory Therapy for Postmenopausal Osteoporosis: A Bibliometric Analysis

  2025cites this paper
• Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study

  2025cites this paper
• Differential fracture risk in breast cancer patients based on endocrine therapy and age: a nationwide cohort study

  2025cites this paper
• Oral Bisphosphonates for Colorectal Cancer Prevention: A Meta-Analytic Reappraisal Beyond Bone Health

  2025cites this paper
• Efficacy of goserelin in ovarian function suppression and preservation for pre- and perimenopausal breast cancer patients: a systematic review

  2025cites this paper
• Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients

  2025cites this paper
• Targeting MDM2, RAS, and PCNA for cancer targeted therapy: pan-cancer approaches vs. cancer-specific strategies

  2025cites this paper
• Hormone receptor-positive early breast cancer in young women: A comprehensive review.

  2024cites this paper
• Breast cancer survivorship

  2024cites this paper
• Synthesis and preliminary anticancer evaluation of photo-responsive prodrugs of hydroxymethylene bisphosphonate alendronate.

  2024cites this paper
• A multifaceted role of bisphosphonates from palliative care to anti-cancer therapy in solid tumors

  2024cites this paper
• Benefit of adjuvant bisphosphonates in early breast cancer treated with contemporary systemic therapy: A meta-analysis of randomized control trials

  2024cites this paper
• How we manage medication-related osteonecrosis of the jaw

  2024cites this paper
• Cancer treatment-induced bone loss

  2024cites this paper
• Evidence-Based Guidance for Breast Cancer Survivorship

  2024cites this paper
• Bone-Active Drugs in Pre-Menopausal Women with Breast Cancer Under Hormone Deprivation Therapies.

  2024cites this paper
• Approach to Bone Health in the Patient with Breast Cancer.

  2024cites this paper
• Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS

  2024cites this paper
• Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis.

  2024cites this paper
• Aromatase inhibitors: the journey from the state of the art to clinical open questions

  2023cites this paper
• The Clinical Benefits of Antiresorptive Agents in Primary Breast Cancer Patients Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis.

  2023cites this paper
• Advances in the care of breast cancer survivors

  2023cites this paper
• Role of Ovarian Suppression in Early Premenopausal Breast Cancer.

  2023cites this paper
• Diagnostic Accuracy of PET with Different Radiotracers versus Bone Scintigraphy for Detecting Bone Metastases of Breast Cancer: A Systematic Review and a Meta-Analysis

  2023cites this paper
• Differences between zoledronic acid and denosumab for breast cancer treatment

  2023cites this paper
• Hypophosphatemia in Patients With Multiple Myeloma

  2023cites this paper
• Evidence-Based Guidance for Breast Cancer Survivorship.

  2023cites this paper
• Risk Factors for Bisphosphonate-Related Osteonecrosis of the Jaws in Bone Metastatic Breast and Prostate Cancer under Zoledronate Treatment: A Retrospective Analysis from 10 Years of Evaluation

  2023cites this paper
• Research Status of Systemic Adjuvant Therapy for Early Breast Cancer

  2023cites this paper
• The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages

  2023cites this paper
• Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis.

  2023cites this paper
• Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting.

  2023cites this paper
• Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies.

  2023cites this paper
• What Is Known about Breast Cancer in Young Women?

  2023cites this paper
• The History of Early Breast Cancer Treatment

  2022cites this paper
• Fracture risk and assessment in adults with cancer

  2022cites this paper
• Effects of zoledronic acid on osteosarcoma progression and metastasis: systematic review and meta‐analysis

  2022cites this paper
• Impact of cytochrome P450 2D6 polymorphisms on decision-making and clinical outcomes in adjuvant hormonal therapy for breast cancer

  2022cites this paper
• Bisphosphonate treatment is associated with decreased mortality rates in patients after osteoporotic vertebral fracture

  2022cites this paper
• Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.

  2022cites this paper
• Pharmacological Prevention and Management of Skeletal-Related Events and Bone Loss in Individuals with Cancer.

  2022cites this paper
• The mevalonate pathway in breast cancer biology.

  2022cites this paper
• Bisphosphonates Targeting Ion Channels and Musculoskeletal Effects

  2022cites this paper
• Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial

  2022cites this paper
• The Impact of Obesity, Adipose Tissue, and Tumor Microenvironment on Macrophage Polarization and Metastasis

  2022cites this paper
• Late Breast Cancer Survivorship: Side Effects and Care Recommendations.

  2022cites this paper
• Detection of genetic mutations in patients with breast cancer from Saudi Arabia using Ion AmpliSeq™ Cancer Hotspot Panel v.2.0

  2022cites this paper
• Letrozole delays acquisition of water maze task in female BALB/c mice: possible involvement of anxiety

  2022cites this paper
• Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials

  2022influential citation
• Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase.

  2022cites this paper
• Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.

  2022cites this paper
• Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

  2022cites this paper
• Synthesis and preliminary anticancer evaluation of new triazole bisphosphonate-based isoprenoid biosynthesis inhibitors.

  2021cites this paper
• The adverse effects of bisphosphonates in breast cancer: A systematic review and network meta-analysis

  2021cites this paper
• Impact of breast cancer and its treatment on bone loss and fracture risk—pathophysiology and management

  2021cites this paper
• Bisphosphonates and risk of lung cancer

  2021cites this paper
• Revisiting Adjuvant Hormone Therapy in Premenopausal Women With Breast Cancer: Escalation and De-Escalation.

  2021cites this paper
• Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience

  2021cites this paper
• Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.

  2021cites this paper
• Cellular Indoctrination: How the Tumor Microenvironment Reeducates Macrophages Towards Nefarious Ends

  2021cites this paper
• Zoledronic acid-loaded lipidic nanoparticles enhance apoptosis and attenuate invasiveness by inhibiting epithelial to mesenchymal transition (EMT) in HepG2 cancer cells

  2021cites this paper
• CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer

  2021cites this paper
• Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020

  2021cites this paper
• Strategies for the treatment of breast cancer: from classical drugs to mathematical models.

  2021cites this paper
• Advance of nano anticancer therapies targeted on tumor-associated macrophages

  2021cites this paper
• Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial.

  2020cites this paper
• Musculoskeletal Health in Premature Ovarian Insufficiency. Part Two: Bone

  2020cites this paper
• Estrogen receptor-mediated targeting of the extracellular matrix network in cancer.

  2020cites this paper
• Treatment of medullary thyroid cancer with bone metastases with denosumab: A review and case illustration

  2020cites this paper
• Recycling the Purpose of Old Drugs to Treat Ovarian Cancer

  2020cites this paper
• Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis

  2020cites this paper
• Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies

  2020cites this paper
• Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score–Matched Cohort Study

  2020cites this paper
• Challenges in preventing bone loss induced by aromatase inhibitors.

  2020cites this paper
• Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab.

  2020cites this paper
• Bisphosphonates and breast cancer - From cautious palliation to saving lives.

  2020cites this paper
• Beyond bone biology: Lessons from team science

  2020cites this paper
• Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.

  2020cites this paper
• Chemistry of Bisphosphonates

  2020cites this paper
• Tumor dormancy in bone

  2020cites this paper
• Molecular mechanisms of actions of bisphosphonates and new insights into their effects outside the skeleton.

  2020cites this paper
• Breast cancer survivorship.

  2020cites this paper
• Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies

  2020cites this paper
• Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

  2020cites this paper
• Post-translational modification of KRAS: potential targets for cancer therapy

  2020cites this paper
• Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.

  2020cites this paper
• Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.

  2020cites this paper
• Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers

  2019cites this paper
• Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

  2019cites this paper
• Formulation and evaluation of cyclodextrin complexes for improved anticancer activity of repurposed drug: Niclosamide.

  2019cites this paper
• Role of zoledronic acid in nasopharyngeal carcinoma patients with bone-only metastasis at diagnosis.

  2019cites this paper
• [LHRH analogs in adjuvant endocrine therapy for pre-menopausal localized breast cancers: Ending the controversy for novel guidelines?]

  2019cites this paper
• Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis

  2019cites this paper
• Chirality-Driven Mode of Binding of α-Aminophosphonic Acid-Based Allosteric Inhibitors of the Human Farnesyl Pyrophosphate Synthase (hFPPS).

  2019cites this paper
• Bone Metastases; Medical Treatment

  2019cites this paper
• Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor‐positive breast cancer: A network meta‐analysis

  2019cites this paper